Results of first week of human trials of QazCovid-in are promising
Human trials of COVID-19 vaccine developed in Kazakhstan have begun in Almaty. 44 volunteers aged from 18 to 50 were injected with this vaccine a week ago at the National Scientific Center of Phthisiopulmonology. They have already done the first blood tests. Developers said that the results are encouraging.
“At the moment, we have identified that our first domestic vaccine against COVID-19 is completely safe and harmless. No reactogenicity was noted during the studies,” said Berik Khairullin, study director of the QazCovid-in vaccine clinical trials.
Earlier, the domestic medicine was successfully tested on laboratory animals, including primates. In August, seven leading scientific experts, the QazCovid-in developers, injected themselves with the vaccine.
“In the future, there will be a second phase of clinical trials. In the first phase we mainly tested safety and immunity, the second phase will focus on immunogenicity and safety. Here 200 volunteers will participate according to the criteria of “inclusion-non-inclusion”, and according to it the vaccination regime will be determined,” said Berik Khairullin, study director of the QazCovid-in vaccine clinical trials.
The QazCovid-in vaccine found out to induce lasting immunity approximately 20 days after its first injection. Berik Khairullin said that double immunization is possible. In the future, the subject of research will be the duration of immunity. At the same time, volunteers must be absolutely healthy, free from chronic infections and any allergic reactions.
“Registration is necessary for the mass use. Now the need for the third phase of research is being determined. However, this phase of research is mainly carried out during the epidemic season, when there is a very large peak in the infection spread. Having decided on these parameters based on the results of the second phase, the need for the third phase will be determined, which, of course, many countries are carrying out. We are also going to conduct these studies,” said Berik Khairullin.
Clinical trials of the coronavirus vaccine are on schedule. Mass use is planned early next year. How exactly the vaccination will be carried out and how much the vaccination will cost will be determined by Kazakh Health Ministry.